INT29983

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 1988
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 9
Disease Relevance 4.44
Pain Relevance 2.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Bad) cell proliferation (Bad) cytosol (Bad)
mitochondrion (Bad) cytoplasm (Bad)
Anatomy Link Frequency
brain 1
3rd ventricle 1
Bad (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 75 100.00 Very High Very High Very High
Clonidine 1 99.96 Very High Very High Very High
narcan 2 96.68 Very High Very High Very High
withdrawal 5 95.68 Very High Very High Very High
tolerance 1 94.16 High High
cINOD 41 94.00 High High
antagonist 11 92.48 High High
noradrenaline 3 88.52 High High
Hippocampus 1 84.16 Quite High
Cannabinoid 5 75.00 Quite High
Disease Link Frequency Relevance Heat
Apoptosis 288 98.92 Very High Very High Very High
Death 40 97.60 Very High Very High Very High
Repression 5 96.64 Very High Very High Very High
Hypoxia 30 95.32 Very High Very High Very High
Colon Cancer 10 86.72 High High
Stress 37 84.52 Quite High
Cancer 20 84.40 Quite High
Reprotox - General 1 1 75.00 Quite High
Endometriosis (extended) 1 75.00 Quite High
INFLAMMATION 33 71.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, some markers of apoptosis were slightly affected (Bak, Caspase 7), while most (including Apaf, Caspase 9, caspase 3, caspase 2, Bcl2 and Bad) were not affected by FOS.


Localization (including) of Bad associated with apoptosis
1) Confidence 0.28 Published 2008 Journal BMC Genomics Section Body Doc Link PMC2311291 Disease Relevance 0.32 Pain Relevance 0
Consistent with reduced Bad translocation to mitochondria, mitochondrial membrane potential is restored and release of cytochrome C and Diablo is suppressed in H2O2-treated cells supplemented with PPAR?
Localization (translocation) of Bad
2) Confidence 0.22 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.76 Pain Relevance 0.21
and increased translocation of Bad to mitochondria leading to apoptosis via the mitochondrial death pathway.
Localization (translocation) of Bad associated with apoptosis and death
3) Confidence 0.22 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 1.34 Pain Relevance 0.64
upregulation increases Bad sequestration, and, therefore, reduces Bad translocation to mitochondria to interfere with the protective action of Bcl-2, an enhanced Bcl-2 expression should further strengthen the protection of mitochondrial membrane potential and reduction of apoptosis.

9.

Localization (translocation) of Bad associated with apoptosis
4) Confidence 0.19 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.65 Pain Relevance 0.03
Analysis of subcellular localization of Bad shows reduced Bad translocation to mitochondria and a reciprocal accumulation of Bad in cytosolic fractions of cells treated with PPAR?
Localization (translocation) of Bad
5) Confidence 0.19 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.57 Pain Relevance 0.08
Analysis of subcellular localization of Bad shows reduced Bad translocation to mitochondria and a reciprocal accumulation of Bad in cytosolic fractions of cells treated with PPAR?
Localization (localization) of Bad
6) Confidence 0.19 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.57 Pain Relevance 0.03
Both the mu- and kappa-agonist stimulated prolactin secretion when infused into the 3rd ventricle, but DAMME was more effective than MR 2034.
Localization (secretion) of kappa-agonist in 3rd ventricle associated with agonist
7) Confidence 0.16 Published 1988 Journal Horm. Res. Section Abstract Doc Link 2851523 Disease Relevance 0 Pain Relevance 0.30
The inhibitory effect of clonidine (alpha2-agonist; 1 mg/kg) on the accumulation of DOPA (15-41%) and 5-HTP (22-41%) was markedly decreased or abolished after chronic WIN and precipitated withdrawal, mainly in noradrenergic and serotonergic brain regions, which indicated desensitization of alpha2-autoreceptors and alpha2-heteroreceptors regulating the synthesis of noradrenaline and 5-HT.
Localization (accumulation) of alpha2-agonist in brain associated with noradrenaline, agonist, withdrawal and clonidine
8) Confidence 0.04 Published 2009 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 18709357 Disease Relevance 0 Pain Relevance 0.98
OBJECTIVE: To examine the utility of a low-dose estrogen and pulsed progestogen hormone replacement therapy (HRT) regimen for add-back during long-term gonadotropin-releasing hormone-agonist (GnRH-agonist) therapy.
Localization (releasing) of hormone-agonist associated with agonist
9) Confidence 0.00 Published 2002 Journal Menopause Section Abstract Doc Link 12082359 Disease Relevance 0.15 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox